Community Fundraising August Wrap-Up
4 September 2019
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA so we can continue to edge closer to our goal of zero deaths from melanoma.
Along with the City2Surf, a number of other running events in August had our community fundraisers moving for melanoma while they raised much-needed funds for MIA. The Sunshine Coast Marathon on August 4 saw Angela Plumb and her three friends raise over $3000 in memory of Angela’s best friend Nicole who sadly passed away recently. In the Chevron City to Surf for Activ in Perth on August 25, teams Kate’s Mates and the Mel A No More’s, and runners Brad Maff, Siobhan Lloyd and Jared Williamson, collectively raised almost $6000 for Melanoma Institute Australia. Thank you to all who participated in these events!
On August 19, the ladies of Randwick Golf Club held their Annual Charity Golf Day and nominated MIA as the beneficiary for 2019. Specifically, the $14,500 raised on the day will contribute to a Phase I Clinical Trial emergency trolley and associated training. The day was a fantastic success, with golf in the morning, then lunch, a raffle, a silent auction and a presentation from MIA Speakers Hub speaker, Julie Randall. Our thanks go out to the ladies of Randwick Golf Club.
Krista Cherry’s mother-in-law, Alison, passed away before she had the chance to meet her grandson. In a beautiful gesture in lieu of gifts, Oliver chooses to raise awareness of melanoma and collect donations in memory of his grandmother. In four years of fundraising, Krista and Oliver have raised almost $6000. Thank you for your generosity!
Peta Willard was a 36-year-old mother of two young boys, a wife, daughter, granddaughter, and teacher who passed away from melanoma earlier in the year. Her touch football team, with the support of the Manly Warringah Touch Association, is rebranding as Willard’s Wombats to compete in the Senior State Cup in December. Their training, however, started with the Pub2Pub Run on August 25, where they raised over $2000 for MIA in honour of Peta and her legacy. Thank you to Willard’s Wombats, and good luck!
Peter and Julie Mansell lost their 25-year-old daughter Morgan to melanoma late last year. As Morgan also had multiple sclerosis and a rare immune deficiency, the Morgan Mansell Fund was created by Peter and Julie to honour their daughter and raise money for the causes close to her heart. With an afternoon of trivia, something Morgan loved to do, a raffle and talks on both Morgan and the Fund held on August 25, the inaugural fundraising event for the Morgan Mansell Fund was a great success.
On August 30, the annual North Queensland Air Conditioning and Refrigeration Golf Day was held at Rowes Bay Golf Club, this year raising funds for MIA in support of their industry colleague and MIA patient, Scott Buckley. A day of golf, lunch and raffles with amazing prizes donated by the community, the day was topped off with speeches from Scott and Melanoma March Townsville Committee Chair Kayla Smith.
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.